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Actinobaculum schaalii can cause urinary tract infec-
tions and septicemia but is difﬁ  cult to identify by cultivation. 
To obtain a fast diagnosis and identify A. schaalii, we devel-
oped a TaqMan real-time quantitative PCR. Routine urine 
samples were obtained from 177 hospitalized patients and 
75 outpatients in Viborg County, Denmark, in 2008–2009. 
The PCR detected A. schaalii in 22% of samples from pa-
tients >60 years of age. This assay showed that A. schaalii 
is more common than implied by routine cultivation. In 90% 
of PCR-positive urine samples, other common uropatho-
gens were identiﬁ  ed. This ﬁ  nding suggests that A. schaalii 
is a common, undetected, bacterial pathogen. Our results 
suggest that A. schaalii may be a more common pathogen 
than previously thought, especially in patients with unex-
plained chronic urinary tract infections, who are often treat-
ed with trimethoprim or ciproﬂ  oxacin, to which A. schaalii is 
resistant.
A
ctinobaculum schaalii was ﬁ  rst described in 1997 and 
named after Klaus P. Schaalii, a German microbiolo-
gist specializing in actinomycete microbiology. The genus 
Actinobaculum includes A. schaalii, A. suis, A. massiliae, 
and A. urinale and is closely related to the genera Actino-
myces and Arcanobacterium (1).
These bacteria are small, gram-positive, facultative an-
aerobic, CO2-requiring coccoid rods. They grow as dimor-
phic gray colonies <1 mm in diameter, are nonmotile and 
non–spore forming, and show weak β-hemolysis on agar 
plates containing 5% horse or sheep blood after 3–5 days 
of growth. They are catalase, oxidase, and urease negative 
and resistant to trimethoprim and ciproﬂ  oxacin (2). Their 
habitat is probably the human genital or urinary tract (1).
Because of its slow growth and resemblance to the nor-
mal bacterial ﬂ  ora on skin and mucosa, A. schaalii is often 
overlooked or considered a contaminant. Furthermore, it is 
often overgrown by faster-growing commensal and patho-
gen bacteria. Most laboratories incubate urine samples only 
overnight in ambient air, which further impedes isolation of 
A. schaalii (2).
Difﬁ  culties identifying A. schaalii by using traditional 
phenotypic tests have obscured its pathologic role for many 
years. However, A. schaalii can cause urinary tract infec-
tions (UTIs), some of which lead to serious illnesses such 
as urosepsis, osteomyelitis, and septicemia, mainly among 
the elderly and patients predisposed to UTIs (1–6). We 
developed a TaqMan real-time quantitative PCR (qPCR) 
speciﬁ  c for the gyrase B (gyrB) gene for fast and sensitive 
detection of A. schaalii from urine and blood samples.
Materials and Methods
Patient and Control Groups
From October 2008 through January 2009, a total of 
252 routine urine samples were randomly selected from 
patients of all ages from 3 hospitals and 150 medical prac-
titioners in Viborg County, Denmark (population ≈230,000 
persons). Seventy percent of patients were from hospitals. 
Urine collection was midstream, from bedpans, from cath-
eters, or unspeciﬁ  ed in 41%, 19%, 18%, and 21% of cases, 
respectively. A total of 38 control urine samples were ob-
tained from patients before they underwent elective surgery 
of hips or knees. These patients were 63–81 years of age 
and had negative results for leukocyte esterase and nitrate 
by a urine dipstick test (Roche Diagnostics Ltd., Burgess 
Hill, UK).
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Cultures and Wet Smear Microscopy of Urine Samples
Samples tested by using PCR were simultaneously an-
alyzed by using standard laboratory tests. These tests were 
wet smear microscopy and incubation on 5% Columbia 
sheep blood agar (Becton Dickinson, Heidelberg, Germa-
ny) in an atmosphere of 5% CO2 at 35°C for 1 or 2 days.
Extraction of DNA
Bacteria were incubated anaerobically on 5% Colum-
bia sheep blood agar in an atmosphere of CO2 at 35°C for 2 
days before harvesting. DNA was puriﬁ  ed by taking a swab 
of bacteria from the agar plate and transferring it to 1 mL 
of saline. The DNA from bacteria was extracted from 800 
μL of saline by using the Kingﬁ  sher mL magnetic particle 
processor (Thermo Electron Corporation, Waltham, MA, 
USA) according to the manufacturer’s instructions, eluted 
in 100 μL elution buffer, and stored at 4°C until use. DNA 
was also obtained from 800-μL urine samples as described 
above.
Sequencing
Fourteen  A.  schaalii strains, including reference 
strain CCUG 27420, were used for sequencing. Univer-
sal primer pair UP-1 and UP-2r was used to amplify the 
gyrB gene from A. schaalii (Table 1). PCR was performed 
as described by Yamamoto and Harayama. (7). The PCR 
product was then gel puriﬁ  ed by using the QIAquick Gel 
Extraction Kit (QIAGEN, Hilgen Germany) and sequenced 
in an ABI 3130 XL genetic analyzer (Applied Biosystems, 
Foster City, CA, USA) according to the manufacturers’ in-
structions. Sequencing primers UP-1S and UP-2Sr (Table 
1) were used to sequence the puriﬁ  ed PCR product in both 
directions. Primers were synthesized by DNA Technology 
(Aarhus, Denmark).
Primers and Probe
Sequence alignment editor BioEdit (www.mbio.ncsu.
edu/BioEdit/BioEdit.html) and Primer3 (http://frodo.
wi.mit.edu/cgi-bin/primer3/primer3_www.cgi) programs 
were used to design a primer and probe speciﬁ  c for A. 
schaalii by multiple alignment of gyrB sequences from 
14 A. schaalii strains, including reference strain CCUG 
27420. Potential primers and probe were analyzed for the 
requirements imposed by real-time PCR by using Prime-
Quest (http://eu.idtdna.com/analyzer/Applications/Oligo-
Analyzer/) and mfold (www.bioinfo.rpi.edu/applications/
mfold/cgi-bin/dna-form1.cgi) programs. Selected primers 
and probe were analyzed for speciﬁ  city against GenBank 
sequences by using the BLAST program (http://blast.ncbi.
nlm.nih.gov/Blast.cgi). 
The primer pair A.s-forward 5′-GGCCATGCAG
TGGACCTC-3′ and A.s-reverse 5′-GCACATCATCA
CCGGAAAGA-3′ ampliﬁ  ed a 185-bp fragment. The probe 
5′-TCCGAATCGGTCAATACCTTCGC-3′ was labeled at 
the 5′ end with 6-carboxyﬂ  uorescein and at the 3′ end with 
Black Hole Quencher 1. Primers and probe were synthe-
sized by Sigma-Aldrich (St. Louis, MO, USA).
TaqMan qPCR
PCR ampliﬁ  cation was performed by using a Mx3000P 
Real Time PCR System (Stratagene, La Jolla, CA, USA) in 
a 25-μL reaction volume. The PCR mixture contained 12 
μL of 2× Brilliant QPCR Master Mixture (Stratagene), 2.5 
μL of 100 nmol/L (ﬁ  nal concentration) TaqMan probe, 2 
μL of 200 nmol/L (ﬁ  nal concentration) forward and reverse 
primers, and 5 μL of template DNA. An internal control 
containing 1.25 μL of internal PCR control primer/probe 
mixture and 0.25 μL of internal PCR control DNA (Ap-
plied Biosystems) was also used. Samples were incubated 
for 1 cycle at 95°C for 2 min and 50 cycles at 95°C for 30 s 
and 60°C for 60 s. All samples were run in duplicate. DNA 
from A. schaalii CCUG 27420 was used as a positive con-
trol and was included in each PCR. Sterile water was used 
as a negative control. Results were analyzed by using the 
Mx3000P software package (Stratagene).
Detection Limit and Quantiﬁ  cation
The detection limit of the A. schaalii gyrB assay was 
determined by using a 10-fold serial dilution of known con-
centrations (1.5 × 101 to 1.5 × 108 CFU/mL) of A. schaalii 
CCUG 27420. Quantiﬁ  cation of A. schaalii in urine sam-
ples was performed by using the same dilution series.
Analytical Speciﬁ  city
To determine the analytical speciﬁ  city of the assay, we 
tested 36 clinical strains of A. schaalii and strain CCUG 
27420. Phylogenetically related (1) and clinically relevant 
bacterial strains, including several Actinomyces spp., Ar-
  Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 16, No. 1, January 2010  77 
Table 1. Sequences of primers and probe used for identification of Actinobaculum schaalii, Denmark, 2008–2009 
Primer or probe  Sequence (5ƍ ĺ 3ƍ) 
UP-1 GAAGTCATCATGACCGTTCTGCAYGCNGGNGGNAARTTYGA 
UP-2r AGCAGGGTACGGATGTGCGAGCCRTCNACRTCNGCRTCNGTCAT 
UP-1S GAAGTCATCATGACCGTTCTGCA 
UP-2Sr AGCAGGGTACGGATGTGCGAGCC 
A.s-forward GGCCATGCAGTGGACCTC 
A.s-reverse GCACATCATCACCGGAAAGA 
A.s-probe TCCGAATCGGTCAATACCTTCGC RESEARCH
canobacterium spp., and reference strains A. suis CCUG 
19026, A. urinale CCUG 46093, and A. massiliae CCUG 
47753, were also tested (Table 2).
Veriﬁ  cation of TaqMan qPCR Assay Results
To verify results of this assay, 6 PCR products were 
sequenced. The ﬁ  rst 15 PCR-positive urine samples were 
cultivated, and isolates were identiﬁ  ed as described by Re-
inhard et. al. (2). Identity of isolated A schaalii strains was 
conﬁ  rmed by using a qPCR.
Puriﬁ  cation of DNA from Blood Cultures
Ten milliliters of blood and 1 mL of culture containing 
2 × 107, 2 × 105, 2 × 103, and 2 × 101 CFU/mL of A. schaa-
lii reference strain CCUG 27420 were added to aerobic 
and anaerobic BACTEC culture vials (Becton Dickinson). 
DNA from bacteria-positive blood cultures was extracted 
from 800 μL of aerobic or anaerobic media and puriﬁ  ed 
by using the Kingﬁ  sher processor as described above.
Because BACTEC culture vials contain sodium polya-
netholesulfonate (SPS), a known PCR inhibitor, either DNA 
must be puriﬁ  ed from BACTEC culture vials by using spe-
ciﬁ  c puriﬁ  cation methods or puriﬁ  ed DNA must be diluted 
to prevent the SPS from inhibiting the PCR (8). Ten-fold 
serial dilutions of puriﬁ  ed DNA from positive BACTEC 
culture vials were made and tested by using the qPCR as 
described above. DNA was extracted from an anaerobic 
BACTEC culture vial from a patient sample from which A. 
schaalii had been isolated by cultivation.
Statistical Analysis
The χ2 test was used to analyze differences in detection 
of A. schaalii. Statistical analyses were performed by using 
SPSS for Windows version 16.0 (SPSS Inc., Chicago, IL, 
USA).
Results
Cultivation of PCR-Positive Samples
Isolates were obtained from 7 of the 15 urine samples 
cultured. The 7 isolates were conﬁ  rmed positive by our 
real-time PCR.
Detection Limit and Analytical Speciﬁ  city
Assay results were linear at bacterial concentrations 
from 1.5 × 104 to 1.5 × 108 CFU/mL with an R2 value of 
1.000 (Y = –3.296 × log(X) + 25.96). The detection limit 
of the assay was between 1.5 × 103 and 1.5 × 104 CFU/mL, 
which corresponds to 7.5–75 CFU/reaction. The assay am-
pliﬁ  ed DNA from all 37 isolates of A. schaalii tested. No 
PCR ampliﬁ  cation signal was detected when other species 
were tested (Table 2).
DNA Sequencing Analysis
The 6 PCR products ampliﬁ  ed from bacteria-positive 
urine samples had the expected size. Sequence alignment 
of the 6 PCR products showed homology to the sequenced 
gyrB gene from A. schaalii strains.
Identiﬁ  cation of A. schaalii from Blood Cultures
The 2 anaerobic BACTEC culture vials to which 1 
mL of 2 × 107 CFU/mL and 2 × 105 CFU/mL had been 
added and 1 aerobic BACTEC culture vials to which 
1 mL of 2 × 107 CFU/mL had been added showed 
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Table 2. Species used to test analytical specificity of gyrase B 
real-time PCR for Actinobaculum schaalii, Denmark, 2008–2009 
Species Source
Actinobaculum spp.
 A.  schaalii CCUG 27420* 
 A.  schaalii† Clinical isolates‡ 
 A.  massiliae CCUG 47753 
 A.  suis CCUG 19026 
 A.  urinale CCUG 46093 
Actinomyces spp.
 A.  gerencseriae Clinical isolates 
 A.  graevenizii Clinical isolates 
 A.  israelii Clinical isolates 
 A.  meyeri Clinical isolates 
 A.  naeslundii Clinical isolates 
 A.  neuii Clinical isolates 
 A.  odontolyticus Clinical isolates 
 A.  radingae Clinical isolates 
 A.  turicencis Clinical isolates 
 A.  urogenitalis Clinical isolates 
 A.  viscosus Clinical isolates 
Arcanobacterium spp.
 A.  bernardiae Clinical isolates 
 A.  hemolyticum Clinical isolates 
 A.  pyogenes Clinical isolates 
Other spp. 
 Gardnerella  vaginalis Clinical isolates 
 Rothia  dentocariosa Clinical isolates 
Common uropathogens 
 Alcaligenes  faecalis Clinical isolates 
 Candida  albicans Clinical isolates 
 Citrobacter  koseri Clinical isolates 
 Escherichia  coli Clinical isolates 
  Hemolytic streptococcus group A  Clinical isolates 
  Hemolytic streptococcus group B  Clinical isolates 
 Klebsiella  oxytoca Clinical isolates 
 K.  pneumoniae Clinical isolates 
 Nonhemolytic  streptococci  Clinical  isolates 
 Proteus  mirabilis Clinical isolates 
 Proteus  vulgaris Clinical isolates 
 Pseudomonas  aeruginosa Clinical isolates 
 Staphylococcus  aureus Clinical isolates 
 Staphylococcus  epidermidis Clinical isolates 
*GenBank accession no. FJ209064. 
†Thirty-six isolates. 
‡GenBank accession nos. FJ518817–FJ518825. Actinobaculum schaalii, a Common Uropathogen
positive results in the BACTEC 9240 blood culture sys-
tem. There was no growth recorded with lower inoculum 
concentrations.
PCR with undiluted and 10-fold diluted DNA was in-
hibited, probably by SPS. However, the 100-fold dilution of 
puriﬁ  ed DNA from the 2 anaerobic and 1 aerobic BACTEC 
culture vials was PCR positive. The 100-fold dilution of 
puriﬁ  ed DNA from a positive anaerobic BACTEC culture 
vial (patient specimen) was also PCR positive.
Analysis of Urine Samples
Of 252 urine samples, 41 (16%) were PCR positive 
with bacterial concentrations >104 CFU/mL. Of 155 urine 
samples from patients >60 years of age, 34 (22%) were 
PCR positive (Table 3), of which 31 (91%) harbored other 
common uropathogenic bacteria in addition to A. schaalii 
(Table 4). Species distribution of these common uropatho-
genic bacteria was comparable to that found in our micro-
biology department throughout the year. Treatment with 
antimicrobial drugs before specimens were obtained was 
reported by 19% of the patients.
The 41 PCR-positive urine samples were collected 
midstream from 37% of patients, from bedpans for 27%, 
from catheters for 12%, and by an unspeciﬁ  ed method for 
24%. Among 177 hospitalized patients, 18% of samples 
from 104 patients >60 years of age and 10% of samples 
from 73 patients <60 years of age were PCR positive (p = 
0.133). Among 75 urine samples obtained by practitioners, 
30% of samples from 51 patients >60 years of age and none 
of the samples from 24 patients <60 years of age were PCR 
positive (p = 0.002). There was no signiﬁ  cant difference 
in the presence of A. schaalii by sex of the patients (p = 
0.485). When the control group (patients who had had hip 
or knee surgery) was compared with patients >60 years of 
age, no signiﬁ  cant difference in the presence of A. schaalii 
was found (p = 0.227). In addition, we did not ﬁ  nd any de-
tectable differences between PCR-positive and PCR-nega-
tive results for hospitalized patients concerning underlying 
urinary tract pathologic changes and concurrent conditions 
such as hypertension and diabetes.
Discussion
The real-time PCR assay conﬁ  rmed that infection with 
A. schaalii increases with age (2). More than 1 of 5 urine 
samples from patients >60 years of age were PCR positive, 
and A. schaalii was most common in patients who visited 
medical practitioners and who had an infection with ordi-
nary urinary pathogens. In comparison, culture ﬁ  ndings in a 
study in our laboratory showed that 0.4% of cultured urine 
samples from patients >60 years of age had A. schaalii and 
that these patients had a broad spectrum of UTIs (2).
The present study shows that bacteria species, espe-
cially anaerobic or slow-growing species, are more com-
mon than what culture results indicate. Most likely, other 
pathogen bacteria exist that are even more difﬁ  cult to iden-
tify by cultivation than is A. schaalii. Molecular biologic 
techniques such as real-time PCR can be valuable tools for 
identiﬁ  cation of these organisms. Pathogenic bacteria that 
are difﬁ  cult to cultivate or identify by cultivation should 
not be underestimated.
Other common uropathogens were identiﬁ  ed by cul-
tivation in 9 of 10 PCR-positive urine samples (Table 4). 
This ﬁ  nding indicates that A. schaalii is probably a com-
mon, undetected bacterial copathogen in many UTIs. Be-
cause most PCR-positive samples were from persons with 
multiple infections, determining which microorganism 
caused the UTI is difﬁ  cult. However, results from our study 
support ﬁ  ndings in case reports (2,3,6) in which A. schaalii 
was often found in monoculture for patients who had UTIs 
and therefore considered the causative agent. Furthermore, 
PCR showed that A. schaalii is a more common pathogen 
than previously thought. However, it will be difﬁ  cult to ful-
ﬁ  ll the last of Koch’s criteria and prove with animal experi-
ments that A. schaalii is a uropathogen.
Clinical microbiologists, clinicians, and medical prac-
titioners should be aware of A. schaalii in patients predis-
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Table 3. Distribution of Actinobaculum schaalii in 252 urine samples, Denmark, 2008–2009* 
CFU/mL of A. schaalii in PCR-positive samples  Age of sample 
donors, y   No. (%) samples  95% CI  10
4–10
5 >10
5–10
6 >10
6–10
7 >10
7
0–10 12 (0) 0 0 0 0
11–20 16 (6) 0 0 0 1
21–30 21 (5) 1 0 0 0
31–40 15 (0) 0 0 0 0
41–50 11 (9) 1 0 0 0
51–60 22 (18) 2 2 0 0
61–70 52 (15) 4 3 0 1
71–80 54 (20) 4 4 1 2
> 8 0 4 9 ( 3 1 ) 3426
<60 97 (7) 3–14 4 2 0 1
>60 155 (22) 16–29 11 11 3 9
Healthy controls  38 (13)  4–28 2 3 0 0
*CI, confidence interval. RESEARCH
posed for UTIs or unexplained chronic UTIs, especially if 
initial ﬁ  ndings of wet smear microscopy for bacterial rods 
and leukocytes differ from negative growth under com-
monly used aerobic cultivation methods. For patients with 
suspected infections, urine should be sent to a department 
of clinical microbiology and incubated in an atmosphere of 
5% CO2 for 2 to 3 days.
For patients with clinically veriﬁ  ed UTIs who do not 
respond to treatment with ciproﬂ  oxacin or trimethoprim, 
infection with A. schaalii should be suspected. If A. schaa-
lii is the cause of the infection, treatment with β-lactams, 
such as ampicillin or cephalosporins, should be given. 
The optimal duration of antimicrobial drug treatment with 
β-lactams is not clearly deﬁ  ned but several weeks of treat-
ment may be required in severe cases.
Because A. schaalii can be difﬁ  cult to identify even 
when cultured in an atmosphere of 5% CO2, the real-time 
PCR described in this report can be used for identiﬁ  cation 
in urine and blood cultures. Alternatively, if the bacteria 
can be isolated by cultivation, the API Coryne and Rapid 
ID32A test systems (bioMérieux, Marcy l’Etoile, France) 
can be used for identiﬁ  cation, as described by Reinhard 
et. al. (2). In conclusion, A. schaalii is an underestimated 
opportunistic copathogen that probably causes UTIs and 
urosepsis, particularly in elderly patients or patients pre-
disposed for UTIs.
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Table 4. Uropathogens identified by cultivation of 155 urine 
samples from patients >60 y of age, Denmark, 2008–2009 
Actinobaculum schaalii
Characteristic PCR positive  PCR negative
Total no. samples  34 121
No growth  3 45
Uropathogens* >10
4 CFU  31 76
Escherichia coli 13 38
Other Enterobacteriaceae 13 14
Other organisms 
 Gram-negative  aerobic 
 rods 
26
 Enterococcus  faecalis 06
 Coagulase-negative   
 staphylococci 
04
 Aerococci  spp. 1 3
 Streptococcus  spp. 2 3
 Yeast  0 2
 >3 species  4 8
*Two species were identified in 4 of 34 PCR-positive samples and in 8 of 
121 PCR-negative samples. 